Profound Medical Corp. (PROF) Financial Analysis & Valuation | Quarter Chart
Profound Medical Corp. (PROF)
PROFPrice: $5.51
Fair Value: 🔒
🔒score
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finl... more
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical devic... more
Description
Shares
| Market Cap | $166.73M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | CA | CEO | Matthew Sobczyk |
| IPO Date | 2019-10-29 | CAGR | — |
| Employees | 142 | Website | www.profoundmedical.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PROF chart loading...
Fundamentals
Technicals
| Enterprise Value | $107.80M | P/E Ratio | -4.05 |
| Forward P/E | -7.59 | PEG Ratio | — |
| P/S Ratio | 266.35 | P/B Ratio | 77.55 |
| P/CF Ratio | -89.75 | P/FCF Ratio | -89.75 |
| EPS | $-1.36 | EPS Growth 1Y | -39.55% |
| EPS Growth 3Y | -42.96% | EPS Growth 5Y | -26.36% |
| Revenue Growth 1Y | -4.98% | Gross Margin | 0.69% |
| Operating Margin | -3.76% | Profit Margin | -3.62% |
| ROE | -0.91% | ROA | -0.83% |
| ROCE | -0.97% | Current Ratio | 8.53 |
| Quick Ratio | 7.07 | Cash Ratio | 6.15 |
| Debt/Equity | 0.12 | Interest Coverage | -214.67 |
| Altman Z Score | -0.98 | Piotroski Score | 3 |